Deletion of the UT receptor gene results in the selective loss of urotensin‐II contractile activity in aortae isolated from UT receptor knockout mice
Authors:
Open Access
- 1 May 2003
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 139 (2) , 464-472
Abstract
Urotensin‐II (U‐II) is among the most potent mammalian vasoconstrictors identified and may play a role in the aetiology of essential hypertension. Currently, only one mouse U‐II receptor (UT) gene has been cloned. It is postulated that this protein is solely responsible for mediating U‐II‐induced vasoconstriction. This hypothesis has been investigated in the present study, which assessed basal haemodynamics and vascular reactivity to hU‐II in wild‐type (UT(+/+)) and UT receptor knockout (UT(−/−)) mice. Basal left ventricular end‐diastolic and end‐systolic volumes/pressures, stroke volumes, mean arterial blood pressures, heart rates, cardiac outputs and ejection fractions in UT(+/+) mice and in UT(−/−) mice were similar. Relative to UT(+/+) mouse isolated thoracic aorta, where hU‐II was a potent spasmogen (pEC50=8.26±0.08) that evoked relatively little vasoconstriction (17±2% 60 mM KCl), vessels isolated from UT(−/−) mice did not respond to hU‐II. However, in contrast, the superior mesenteric artery isolated from both the genotypes did not contract in the presence of hU‐II. Reactivity to unrelated vasoconstrictors (phenylephrine, endothelin‐1, KCl) and endothelium‐dependent/independent vasodilator agents (carbachol, sodium nitroprusside) was similar in the aorta and superior mesenteric arteries isolated from both the genotypes. The present study is the first to directly link hU‐II‐induced vasoconstriction with the UT receptor. Deletion of the UT receptor gene results in loss of hU‐II contractile action with no ‘nonspecific’ alterations in vascular reactivity. However, as might be predicted based on the limited contractile efficacy recorded in vitro, the contribution that hU‐II and its receptor make to basal systemic haemodynamics appears to be negligible in this species. British Journal of Pharmacology (2003) 139, 464–472. doi:10.1038/sj.bjp.0705254Keywords
This publication has 44 references indexed in Scilit:
- Inhibition of Insulin Release by Urotensin II - A Study on the Perfused Rat PancreasHormone and Metabolic Research, 2001
- Human urotensin‐II is a potent spasmogen of primate airway smooth muscleBritish Journal of Pharmacology, 2000
- Human urotensin‐II is an endothelium‐dependent vasodilator in rat small arteriesBritish Journal of Pharmacology, 2000
- Contractile responses to human urotensin‐II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the ratBritish Journal of Pharmacology, 2000
- Identification of Urotensin II as the Endogenous Ligand for the Orphan G-Protein-Coupled Receptor GPR14Biochemical and Biophysical Research Communications, 1999
- Native Urotensins Influence Cortisol Secretion and Plasma Cortisol Concentration in the Euryhaline Flounder,Platichthys flesusGeneral and Comparative Endocrinology, 1998
- Salt-Sensitive Hypertension in Bradykinin B2Receptor Knockout MiceBiochemical and Biophysical Research Communications, 1996
- Cloning and Chromosomal Mapping of Three Novel Genes, GPR9, GPR10, and GPR14, Encoding Receptors Related to Interleukin 8, Neuropeptide Y, and Somatostatin ReceptorsGenomics, 1995
- A Novel Putative Neuropeptide Receptor Expressed in Neural Tissue, Including Sensory EpitheliaBiochemical and Biophysical Research Communications, 1995
- Isolation and primary structure of urotensin II from the brain of a tetrapod, the frog Rana ridibundaBiochemical and Biophysical Research Communications, 1992